$MRNA, $ALNY, $GMAB, $BGNE, $ROIV, $HALO, and $PCVX: Biotech sector stocks that have fallen by over 10% in the past month.
Some biotech sector stocks have experienced more significant declines in the past month compared to the overall market, with drops exceeding 10%. For quick trade insights, you can subscribe to our robots at Swing-Trader-High-Volatility-Stocks-for-Active-Trading-TA-FA.
The group's average market capitalization is $21.3 billion, ranging from $7.9 billion (ROIV) to $37.4 billion (MRNA).
In terms of price performance, the average weekly change was -4.48%, monthly change was -12.29%, and quarterly change was -13.57%. Notably, BGNE had the highest weekly price growth at 2.82%, while GMAB experienced the largest decline at -8.22%.
Regarding trading volume, the group had an average weekly volume growth of 19.56%. Monthly volume growth averaged 22.22%, and quarterly volume growth averaged 48.52%.
In terms of fundamental analysis ratings (scale: 1 to 100, with 1 being the best and 100 being the worst):
- Valuation Rating: 74
- P/E Growth Rating: 76
- Price Growth Rating: 65
- SMR Rating: 77
- Profit Risk Rating: 70
The Seasonality Score is 25 on a scale of -100 to +100.
MRNA's Stochastic Oscillator exited the overbought zone on October 12, 2023, signaling a potential bearish trend with a 90% likelihood of a decline.
- MRNA Current price: $98.30; trading between $175.56 resistance and $69.57 support lines. It experienced a -9% Downtrend in the month of 09/13/23 - 10/13/23, with a -5% weekly fall.
GMAB's MACD Histogram turned negative on October 12, 2023, suggesting a potential stock decline with a 69% probability.
- GMAB Current price: $32.28; below the $33.91 lowest support line. It faced an -11% Downtrend in the month of 09/13/23 - 10/13/23, dropping -8% weekly.
BGNE's RSI Oscillator exited the oversold zone on October 05, 2023, indicating a potential shift from a downtrend to an uptrend with an 82% probability.
- BGNE Current price: $178.79; below the $239.67 lowest resistance line. It experienced an -11% Downtrend in the month of 09/13/23 - 10/13/23, but showed a +3% Uptrend in the week of 10/06/23 - 10/13/23.
ROIV's RSI Oscillator moved out of the overbought zone on September 28, 2023, hinting at a possible shift from an uptrend to a downtrend with a 78% chance of a decline.
- ROIV Current price: $10.08; above the $8.59 highest resistance line. It faced a -10% Downtrend during the month of 09/13/23 - 10/13/23 and declined -7% weekly.
HALO's Momentum Indicator turned negative on September 26, 2023, suggesting a new potential downward trend with a 69% likelihood.
- HALO Current price: $36.55; below the $39.43 lowest support line. It experienced an -11% Downtrend during the month of 09/13/23 - 10/13/23 and fell -2% weekly.
PCVX's Stochastic Oscillator has been in the oversold zone for 1 day, indicating a potential upcoming price bounce.
- PCVX Current price: $46.00; trading between $61.37 resistance and $23.75 support lines. It experienced an -11% Downtrend during the month of 09/13/23 - 10/13/23 and declined -6% weekly.
HALO in +1.43% Uptrend, advancing for three consecutive days on June 12, 2025
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where HALO advanced for three days, in of 315 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for HALO just turned positive on May 30, 2025. Looking at past instances where HALO's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 09, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on HALO as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HALO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HALO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.369) is normal, around the industry mean (16.539). P/E Ratio (13.915) is within average values for comparable stocks, (59.016). HALO's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.300). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (6.219) is also within normal values, averaging (255.605).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an international biotechnology company, which develops human antibody therapeutics for the treatment of cancer and other diseases.
Industry Biotechnology